<?xml version="1.0" encoding="UTF-8"?>
<p id="p0160">Using methods of machine learning-enabled scientific literature analysis, the biotech company BenevolentAI proposed the AP2-associated protein kinase 1 (AAK1) as a host target to fight SARS-CoV-2. AAK1 is the key enzyme of receptor-mediated endocytosis, which is the major mechanism of most viruses to enter their host cells. Thus, they predict the approved (for rheumatoid arthritis) kinase inhibitor baricitinib 
 <bold>29</bold> to reduce the ability of the virus to infect lung cells (
 <xref rid="fig8" ref-type="fig">FigureÂ 8</xref> ).
 <xref rid="bib46" ref-type="bibr">
  <sup>46</sup>
 </xref>
</p>
